Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics

    199499_123417_Al-Salami_JPharmInn_2014.pdf (618.4Kb)
    Access Status
    Open access
    Authors
    Mooranian, Armin
    Negrulj, Rebecca
    Mathavan, Sangeetha
    Martinez, Jorge
    Sciarretta, Jessica
    Chen-Tan, Nigel
    Mukkur, Trilochan
    Mikov, Momir
    Lalic-Popovic, M.
    Stojancevic, M.
    Golocorbin-Kon, S.
    Al-Salami, Hani
    Date
    2014
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Mooranian, A. and Negrulj, R. and Mathavan, S. and Martinez, J. and Sciarretta, J. and Chen-Tan, N. and Mukkur, T. et al. 2014. Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. Journal of Pharmaceutical Innovation. 9 (2): pp. 150-157.
    Source Title
    Journal of Pharmaceutical Innovation
    DOI
    10.1007/s12247-014-9182-5
    ISSN
    1872-5120
    School
    School of Pharmacy
    Remarks

    This open access article is distributed under the Creative Commons license http://creativecommons.org/licenses/by/4.0/

    URI
    http://hdl.handle.net/20.500.11937/14090
    Collection
    • Curtin Research Publications
    Abstract

    Introduction: In previous studies carried out in our laboratory, a bile acid (BA) formulation exerted a hypoglycaemic effect in a rat model of type-1 diabetes (T1D). When the antidiabetic drug gliclazide (G) was added to the bile acid, it augmented the hypoglycaemic effect. In a recent study, we designed a new formulation of gliclazide-cholic acid (G-CA), with good structural properties, excipient compatibility and exhibits pseudoplastic-thixotropic characteristics. The aim of this study is to test the slow release and pH-controlled properties of this new formulation. The aim is also to examine the effect of CA on G release kinetics at various pH values and different temperatures. Method: Microencapsulation was carried out using our Buchi-based microencapsulating system developed in our laboratory. Using sodium alginate (SA) polymer, both formulations were prepared: G-SA (control) and G-CA-SA (test) at a constant ratio (1:3:30), respectively. Microcapsules were examined for efficiency, size, release kinetics, stability and swelling studies at pH 1.5, pH 3, pH 7.4 and pH 7.8 and temperatures of 20 and 30 °C. Results: The new formulation is further optimised by the addition of CA. CA reduced microcapsule swelling of the microcapsules at pH 7.8 and pH 3 at 30 °C and pH 3 at 20 °C, and, even though microcapsule size remains similar after CA addition, percent G release was enhanced at high pH values (pH 7.4 and pH 7.8, p < 0.01). Conclusion: The new formulation exhibits colon-targeted delivery and the addition of CA prolonged G release suggesting its suitability for the sustained and targeted delivery of G and CA to the lower intestine.

    Related items

    Showing items related by title, author, creator and subject.

    • High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect
      Golocorbin-Kon, S.; Calasan, J.; Milijasevic, B.; Vukmirovic, S.; Lalic-Popovic, M.; Mikov, M.; Al-Salami, Hani (2017)
      Background and objective: Gliclazide is a drug commonly used in type 2 diabetes mellitus. Recently, gliclazide has shown desirable pharmacological effects such as immunoregulatory and anti-clotting effects, which suggests ...
    • Pharmacokinetic and Drug Absorption Profiles of the Anti-Hyperglycaemic Agent Gliclazide in Oral Tissue-Targeted Microcapsules in Rats
      Jovic, Jelena; Milijasevic, Boris; Vukmirovic, Sasa; Vasovic, Velibor; Mikov, Momir; Mooranian, Armin; Al-Salami, Hani ; Golocorbin-Kon, Svetlana (2020)
      Background/Aim: Gliclazide is one of the most commonly prescribed oral anti-hyperglycaemic therapies in type 2 diabetes mellitus (T2D). Recently reported additional beneficial pharmacological properties of gliclazide, ...
    • Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment
      Mooranian, Armin; Negrulj, Rebecca; Al-Sallami, H.; Fang, Zhongxiang; Mikov, M.; Golocorbin-Kon, S.; Fakhoury, M.; Arfuso, Frank; Al-Salami, Hani (2015)
      In previous studies carried out in our laboratory, a bile acid formulation exerted a hypoglycaemic effect in a rat model of type 1 diabetes (T1D). When the antidiabetic drug gliclazide was added to the bile acid, it ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.